RCKT - Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) has received a consensus rating of "Hold" from the ten analysts that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and one has issued a strong
RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today reported financial and recent operational results for the second quarter ended June 30, 2026. “The second quarter of 2026 materially strengthened Rocket's position, with the approval of KRESLADI demonstrating our ability to advance a genetic medi.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) on Monday shared a clinical safety update concerning the first three patients treated in its global, pivotal Phase 2 trial for Danon disease.
[url="]Rocket Pharmaceuticals, Inc.[/url] (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic m
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today announced a positive clinical safety update regarding the initial three patients treated under the modified protocol for its global, pivotal Phase 2 trial of RP-A501 in Danon disease. Early safety has been promising with t.
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $180 million. The Rare Pediatric Disease Priority Review Voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI.
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference in New York and Miami, respectively. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside ch.
Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the first quarter ended March 31, 2026. “During the first quarter, we continued advancing our cardiovascular gene therapy portfolio, including reinitiating dosing in the initial three-patient cohort of our p.
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strengthened financial position following the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). Rocket has entered into a definitive agreement to sell its PRV for $180 million. The PRV was awarded following the U.S. Food and Drug Adm.
Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.
Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Rocket Pharmaceuticals (NASDAQ: RCKT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends. Profitability This table compares Foghorn Therapeutics and
Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript
Rocket Pharmaceuticals (NASDAQ:RCKT) announced that the US Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI (marnetegragene autotemcel), the company's gene therapy for children with severe leukocyte adhesion deficiency-I (LAD-I) caused by biallelic variants in ITGB2. The therapy is intended for patients without an available human leukocyte antigen-matched sibling donor for allogeneic stem cell transplant.
Rocket Pharmaceuticals shares jumped 10% on Friday before the bell after the U.S. Food and Drug Administration approved its gene therapy for a rare and often fatal immune disorder in children, marking the first regulatory green light for a treatment of the condition.
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel), an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients with severe leukocyte adhesion defici.
Rocket Pharmaceuticals (NASDAQ:RCKT) announced that the US Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI (marnetegragene...